LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Locked nucleic acid (LNA) is a nucleic acid analogue containing one or more LNA nucleotide monomers with a bicyclic furanose unit locked in an RNA mimicking sugar conformation. LNA oligonucleotides display unprecedented hybridization affinity toward complementary single-stranded RNA and complementary single- or double-stranded DNA. Structural studies have shown that LNA oligonucleotides induce A-type (RNA-like) duplex conformations. The wide applicability of LNA oligonucleotides for gene silencing and their use for research and diagnostic purposes are documented in a number of recent reports, some of which are described herein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antisense oligonucleotides are an attractive therapeutic strategy because they can inhibit mRNA expression specifically [7, 8].”
From Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors (2014) · cites this paper as [8]
Citations
Cites
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Self-citationAn autonomous molecular computer for logical control of gene expression
Benenson, Y., Gil, B., Ben-Dor, U., Adar, R., & Shapiro, E. (2004) · Nature · doi:10.1038/nature02551 · Cited by 821
LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition
Singh, S. K., Koshkin, A. A., Wengel, J., & Nielsen, P. (1998) · Chemical Communications · doi:10.1039/a708608c · Cited by 768
Self-citationObika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
LNA: a versatile tool for therapeutics and genomics
Petersen, M., & Wengel, J. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(02)00038-0 · Cited by 613
Self-citationObika, S., Nanbu, D., Hari, Y., Morio, K.-I., In, Y., Ishida, T., & Imanishi, T. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)10322-7 · Cited by 610
Design of antisense oligonucleotides stabilized by locked nucleic acids
Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 577
RNA Interference in Mammalian Cells by Chemically-Modified RNA
Braasch, D. A., Jensen, S., Liu, Y., Kaur, K., Arar, K., White, M. A., & Corey, D. R. (2003) · Biochemistry · doi:10.1021/bi0343774 · Cited by 531
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520
Self-citation
Research works printed but not linked: 39
- Jepsen J. S., 2004, Curr. Opin. Drug Discovery Dev. 7, 188−194.
- Singh S. K., 1998, Chem. Commun. 4, 455−456.
- Koshkin A. A., 1998, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition, Tetrahedron 54, 3607−3630.
- Wengel J., 1999, Acc. Chem. Res. 32, 301−310.
- McTigue P. M., 2004, Biochemistry 43, 5388−5405.
- Nielsen K. E., 2004, Bioconjugate Chem. 15, 449−457.
- Nielsen K. M. E., 2002, Chem.Eur. J., 8
- Nielsen J. T., 2003, Nucleic Acids Res. 31, 5858−5867.
- Wahlestedt C., 2000, Proc. Natl. Acad. Sci. U.S.A. 97
- Kurreck J., 2002, Nucleic Acids Res. 30
- Frieden M., 2003, Nucleic Acids Res. 31, 6365−6372.
- Crinelli R., 2002, Nucleic Acids Res. 30, 2435−2443.
- Santoro S. W., 1997, Proc. Natl. Acad. Sci. U.S.A. 94
- Schubert S., 2003, DNAzymes with enhanced stability and activity, Nucleic Acids Res. 31, 5982−5992.
- Fahmy R. G., 2004, Nucleic Acids Res. 32, 2281−2285.
- Obika S., 2001, Nucleic Acids Res. Suppl., 145−146.
- Hansen J. B., 2003, Nucleosides, Nucleotides Nucleic Acids 22, 1607−1609.
- Elayadi A. N., 2002, Biochemistry 41, 9973−9981.
- Childs J. L., 2002, Proc. Natl. Acad. Sci. U.S.A. 99
- Ittig D., 2004, Nucleic Acids Res. 32, 346−353.
- Grünweller A., 2003, Nucleic Acids Res. 31, 3185−3193.
- Braasch D. A., 2003, Biochemistry 42, 7967−7975.
- Schwarz D. S., 2003, Cell 115, 199−208.
- Arzumanov A., 2003, Oligonucleotides 13, 435−453.
- Buchini S., 2003, Curr. Opin. Chem. Biol. 7, 717−726.
- Obika S., 2000, Tetrahedron Lett., 41
- Obika S., 2001, Chem. 9, 1001−1011.
- Sun B. W., 2004, Biochemistry 43, 4160−4169.
- Goni J. R., 2004, Nucleic Acids Res. 32, 354−360.
- Hertoghs K. M., 2003, Nucleic Acids Res. 31, 5817−5830.
- Jacobsen N., 2002, Clin. Chem. 48, 657−660.
- Ørum H., 1999, Clin. Chem. 45
- Ugozzoli L. A., 2004, Anal. Biochem. 324, 143−152.
- Letertre C., 2003, Mol. Cell Probes 17, 307−311.
- Tolstrup N., 2003, Nucleic Acids Res. 31, 3758−3762.
- Silahtaroglu A. N., 2003, Mol. Cell Probes 17, 165−169.
- Sørensen M. D., 2003, Chem. Commun. 17, 2130−2131.
- Benenson Y., 2004, Nature 429, 423−429.
- Abbreviations LNA, locked nucleic acid
Cited by
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
“By locking the molecule with the methylene bridge, LNA oligonucleotides display unprecedented hybridization affinity towards complementary single-stranded RNA and complementary single-stranded or double-stranded DN”
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Critical review on biofilm methods
Azeredo, J., Azevedo, N. F., Briandet, R., Cerca, N., Coenye, T., Costa, A. R., Desvaux, M., Di Bonaventura, G., Hébraud, M., Jaglic, Z., et al. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2016.1208146 · Cited by 1,045
“Chemically speaking, these mimics differ from DNA or RNA by modifications at the level of the back-bone, both in the phosphate group and in the pentose sugar (Nielsen et al., 1991; Vester & Wengel, 2004).”
BackgroundFazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M. L., Nervi, C., & Bozzoni, I. (2005) · Cell · doi:10.1016/j.cell.2005.09.023 · Cited by 894
microRNAs in cancer management
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70073-6 · Cited by 734
Molecular Engineering of DNA: Molecular Beacons
Wang, K., Tang, Z., Yang, C. J., Kim, Y., Fang, X., Li, W., Wu, Y., Medley, C. D., Cao, Z., Li, J., et al. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200800370 · Cited by 644
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
“In addition, structural studies have shown that the fixed N -type conformation of the LNA nucleoside preorganizes LNA oligonucleotides in a high-affinity conformation for binding complementary RNA sequences, thereby adopting an A-form helix geometry typical for RNA-RNA duplexe”
BackgroundIn situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes
Kloosterman, W. P., Wienholds, E., de Bruijn, E., Kauppinen, S., & Plasterk, R. H. A. (2006) · Nature Methods · doi:10.1038/nmeth843 · Cited by 599
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
“LNAs are nucleic acid analogs with a 20O to 40C methylene bridge that locks the ribose group into a C30 endo conformation (26, 27).”
Purification of Proteins Associated with Specific Genomic Loci
Déjardin, J., & Kingston, R. E. (2009) · Cell · doi:10.1016/j.cell.2008.11.045 · Cited by 546
“To increase the stability of the probe-chromatin interactions, we used locked nucleic acid (LNA) containing oligonucleotides as probes because LNA residues have an altered backbone that favors base stacking thereby significantly increasing their melting temperature (Vester and Wengel, 2004).”
Long Noncoding RNA in Cancer: Wiring Signaling Circuitry
Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488
“The Locked nucleic acids (LNAs) [90, 94, 95] and S-constrained ethyl (cEt) modifications [96] have been advanced to clinical trials [97–99].”
BackgroundShi, X.-B., Xue, L., Yang, J., Ma, A.-H., Zhao, J., Xu, M., Tepper, C. G., Evans, C. P., Kung, H.-J., & deVere White, R. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706641104 · Cited by 378
microRNA Therapeutics in Cancer — An Emerging Concept
Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.017 · Cited by 453
“Another example of modified AMOs are the Locked Nucleic Acid (LNA) anti-miRs, in which an extra methylene bridge connecting the 2′-O atom and the 4′-C atom ‘locks’ the ribose ring in a C3′-endo or C2′-endo conformation (Vester and Wengel, 2004; Elmen et al., 2008).”
BackgroundMethodological challenges in utilizing mi RNA s as circulating biomarkers
Moldovan, L., Batte, K. E., Trgovcich, J., Wisler, J., Marsh, C. B., & Piper, M. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12236 · Cited by 436
“The capture probes have been designed using their LNA technology [21].”
MethodANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H., Lim, S., & Wong, W. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 430
“affinity towards target mRNA and DNA, with a substantial increase in the thermal stability of the duplexes.(33) In addition, LNA is resistant to nuclease degradation.”
BackgroundGleave, M. E., & Monia, B. P. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1631 · Cited by 384
MiR-210 – micromanager of the hypoxia pathway
Huang, X., Le, Q.-T., & Giaccia, A. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.03.004 · Cited by 376
Rationally designed molecular beacons for bioanalytical and biomedical applications
Zheng, J., Yang, R., Shi, M., Wu, C., Fang, X., Li, Y., Li, J., & Tan, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00020c · Cited by 372
Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?
Weiler, J., Hunziker, J., & Hall, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302654 · Cited by 371
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
“The modified structure also provides good solubility and metabolic stability in vivo [138].”
BackgroundsiRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
He, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., Li, P.-Y., Song, Y.-H., & Lin, J.-S. (2012) · Oncogene · doi:10.1038/onc.2011.500 · Cited by 339
“, 2009), or locked nucleic acid-modified oligonucleotides (Vester and Wengel, 2004) is worthy to be further determined for the anticancer treatment of HCC.”
BackgroundHarris, J. A., Devidze, N., Verret, L., Ho, K., Halabisky, B., Thwin, M. T., Kim, D., Hamto, P., Lo, I., Yu, G.-Q., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.020 · Cited by 319
“The LNA technology improves specific hybridization to short target sequences (Koshkin et al., 1998; Vester and Wengel, 2004).”
RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain
NELSON, P. T., BALDWIN, D. A., KLOOSTERMAN, W. P., KAUPPINEN, S., PLASTERK, R. H. A., & MOURELATOS, Z. (2006) · RNA · doi:10.1261/rna.2258506 · Cited by 297
“…subtype of small ( 22 nucleotide) regulatory RNAs (for reviews, see Nelson et al. 2003; Ambros 2004; Bartel 2004; Meister and Tuschl 2004; Wienholds and Plasterk 2005). miRNAs bind directly to Argonaute (Ago) proteins and form effector complexes known as RNA-induced silencing complexes…”
BackgroundNew insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer
Yao, Z., Yang, Y., Sun, M., He, Y., Liao, L., Chen, K., & Li, B. (2022) · Cancer Communications · doi:10.1002/cac2.12254 · Cited by 288
Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)
Kaur, H., Babu, B. R., & Maiti, S. (2007) · Chemical Reviews · doi:10.1021/cr050266u · Cited by 285
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Macrophages, Chronic Inflammation, and Insulin Resistance
Li, H., Meng, Y., He, S., Tan, X., Zhang, Y., Zhang, X., Wang, L., & Zheng, W. (2022) · Cells · doi:10.3390/cells11193001 · Cited by 264
MicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
“LNA is a changed oligonucleotide that has a therapeutic potential with low toxicity, elevated affinity, and high stability and specificity in vivo (Flynt, Li, Thatcher, Solnica‐Krezel, & Patton, 2007; Kumar, El‐ Sagheer, Truong, & Brown, 2017; Vester & Wengel, 2004).”
BackgroundAnalytical aspects of microRNA in diagnostics: A review
de Planell-Saguer, M., & Rodicio, M. C. (2011) · Analytica Chimica Acta · doi:10.1016/j.aca.2011.05.025 · Cited by 261
Biswas, C., Shah, N., Muthu, M., La, P., Fernando, A. P., Sengupta, S., Yang, G., & Dennery, P. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567685 · Cited by 256
“For this purpose, we pre-annealed an isosequential all-LNA 8-mer (LNA, locked nucleic acid (Vester and Wengel, 2004; Grünweller and Hartmann, 2007); all-LNA, LNA analogues”
MethodDNA-programmed assembly of nanostructures
Gothelf, K. V., & LaBean, T. H. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b510551j · Cited by 253
Optimization and Modifications of Aptamers Selected from Live Cancer Cell Lines
Shangguan, D., Tang, Z., Mallikaratchy, P., Xiao, Z., & Tan, W. (2007) · ChemBioChem · doi:10.1002/cbic.200600532 · Cited by 250
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
“high target mRNA binding affinity and extraordinary tissue stability (28, 29).”
BackgroundLocked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications
Veedu, R. N., & Wengel, J. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900343 · Cited by 240
Self-citationAsl, E. R., Amini, M., Najafi, S., Mansoori, B., Mokhtarzadeh, A., Mohammadi, A., Lotfinejad, P., Bagheri, M., Shirjang, S., Lotfi, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119499 · Cited by 231
Nanoparticles and DNA – a powerful and growing functional combination in bionanotechnology
Samanta, A., & Medintz, I. L. (2016) · Nanoscale · doi:10.1039/c5nr08465b · Cited by 231
A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies
Forterre, A., Komuro, H., Aminova, S., & Harada, M. (2020) · Cancers · doi:10.3390/cancers12071852 · Cited by 227
Host-virus interaction: a new role for microRNAs
Scaria, V., Hariharan, M., Maiti, S., Pillai, B., & Brahmachari, S. K. (2006) · Retrovirology · doi:10.1186/1742-4690-3-68 · Cited by 220
“Recent advances in nucleotide chemistry like Locked Nucleic Acids (LNA) [ 57 ], and other backbone modifications have made it possible to design small RNA oligonucleotides which are highly stable in biological systems circumventing one major hurdle in using microRNAs as future therapeutics.”
BackgroundBioinformatic tools for microRNA dissection
Akhtar, M. M., Micolucci, L., Islam, M. S., Olivieri, F., & Procopio, A. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1221 · Cited by 215
“Several miRNA inhibitory agents have been tested in preclinical and clinical studies; they include antisense antimiR oligonucleotides (30), locked nucleic acid antimiRs (50), miRNA sponges (51), miRNA masks (52) and smallmolecule miRNA inhibitors (53).”
MicroRNAs as potential cancer therapeutics
Trang, P., Weidhaas, J. B., & Slack, F. J. (2008) · Oncogene · doi:10.1038/onc.2009.353 · Cited by 208
“As an alternative to 20-hydroxyl-modified AMOs, lock nucleic acid (LNA)-based oligonucleotides (LNA-antimiR) have been shown to be more stable and less toxic in inhibiting endogenous miRNAs in vivo (Vester and Wengel, 2004; Elmen et al., 2008).”
BackgroundZhou, C.-Y., Zhao, J., Wu, Y.-B., Yin, C.-X., & Pin, Y. (2007) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.07.011 · Cited by 200
Circulating miRNA analysis for cancer diagnostics and therapy
Valihrach, L., Androvic, P., & Kubista, M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.10.002 · Cited by 199
The utility of LNA in microRNA-based cancer diagnostics and therapeutics
Stenvang, J., Silahtaroglu, A. N., Lindow, M., Elmen, J., & Kauppinen, S. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.01.004 · Cited by 198
Two-tailed RT-qPCR: a novel method for highly accurate miRNA quantification
Androvic, P., Valihrach, L., Elling, J., Sjoback, R., & Kubista, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx588 · Cited by 198
“Modified primers may have higher melting temperature (Tm) and enhanced sequence discrimination (52).”
BackgroundMicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
To, K. K., Tong, C. W., Wu, M., & Cho, W. C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i27.2949 · Cited by 198
Bramsen, J. B., Pakula, M. M., Hansen, T. B., Bus, C., Langkjær, N., Odadzic, D., Smicius, R., Wengel, S. L., Chattopadhyaya, J., Engels, J. W., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq341 · Cited by 195
“Continued Name AS/SS Modification Sequence (50-30) W361 AS2 UNA 7 ACUUCAGUNAGGUCAGCUUGCCTLNATLNAU W362 AS2 OMe 2 ACOMeUUCAGGGUCAGCUUGCCTLNATLNAU W363 AS2 DNA 1-8 ADNACDNAUDNAUDNACDNAADNAGDNAGDNAGUCAGCUUGCCTLNATLNAU W364 SS2 RNA GGCAAGCUGACCCUGAAGUUC W367 AS2 UNA 2 ACUNAUUCAGGGUCAGCUUGCCTLNATLNAU W368 AS2 UNA 3 ACUUNAU…”
BackgroundSelf-citationDNA Nanostructures: Current Challenges and Opportunities for Cellular Delivery
Lacroix, A., & Sleiman, H. F. (2021) · ACS Nano · doi:10.1021/acsnano.0c06136 · Cited by 190
Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity
Cromwell, C. R., Sung, K., Park, J., Krysler, A. R., Jovel, J., Kim, S. K., & Hubbard, B. P. (2018) · Nature Communications · doi:10.1038/s41467-018-03927-0 · Cited by 190
miRNAs as Modulators of Angiogenesis
Landskroner-Eiger, S., Moneke, I., & Sessa, W. C. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006643 · Cited by 190
“As an alternative to 20-hydroxyl-modified AMOs, lock nucleic acid (LNA)–based oligonucleotides (LNA-antimiRs) have been shown to be more stable and less toxic in inhibiting endogenous miRNAs in vivo (Vester and Wengel 2004; Elmen et al. 2008).”
Metastamirs: a stepping stone towards improved cancer management
White, N. M. A., Fatoohi, E., Metias, M., Jung, K., Stephan, C., & Yousef, G. M. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.173 · Cited by 184
MicroRNAs: critical mediators of differentiation, development and disease
Friedman, J., & Jones, P. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12794 · Cited by 159
Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2362-z · Cited by 159
“Antisense oligonucleotides are an attractive therapeutic strategy because they can inhibit mRNA expression specifically [7, 8].”
BackgroundStability and Mismatch Discrimination of Locked Nucleic Acid–DNA Duplexes
Owczarzy, R., You, Y., Groth, C. L., & Tataurov, A. V. (2011) · Biochemistry · doi:10.1021/bi200904e · Cited by 167
Nucleic‐Acid Structures as Intracellular Probes for Live Cells
Samanta, D., Ebrahimi, S. B., & Mirkin, C. A. (2019) · Advanced Materials · doi:10.1002/adma.201901743 · Cited by 160
Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery
Raouane, M., Desmaële, D., Urbinati, G., Massaad-Massade, L., & Couvreur, P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200422w · Cited by 165
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 154
“…indisulam induced sequelae, such as disruption of the G1/G2 phases of the cell cycle and expression changes of genes related to cell adhesion, cell signaling, and altered glucose metabolism (Owa et al., 1999; Rapisarda et al., 2002; Rapisarda & Zalek et al., 2004b; Vester & Wengel, 2004).”
BackgroundMethodThe role of microRNAs in cancer.
Stahlhut, C. E., & Slack, F. (2006) · PubMed Central · Cited by 188
MicroRNA Involvement in Osteosarcoma
Kobayashi, E., Hornicek, F. J., & Duan, Z. (2012) · Sarcoma · doi:10.1155/2012/359739 · Cited by 151
Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme
Karsy, M., Arslan, E., & Moy, F. (2012) · Genes & Cancer · doi:10.1177/1947601912448068 · Cited by 151
“Another method includes locked nucleic acid (LNA) constructs, consisting of nucleic acids with methylene bridges between the 2′-O and 4′-C atoms in the ribose ring, and have been used to knock down miR expression.(89) Despite these advances, challenges in the delivery of miRs to target sites as well as regulation of u…”
MethodEnhancement of the Seed-Target Recognition Step in RNA Silencing by a PIWI/MID Domain Protein
Parker, J. S., Parizotto, E. A., Wang, M., Roe, S. M., & Barford, D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.012 · Cited by 150
“These observations are reminiscent of the properties of Locked Nucleic Acids (LNAs), which also confer enhanced affinity for complementary nucleic acid strands (McTigue et al., 2004; Vester and Wengel, 2004).”
BackgroundLNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas
Zhang, Y., Roccaro, A. M., Rombaoa, C., Flores, L., Obad, S., Fernandes, S. M., Sacco, A., Liu, Y., Ngo, H., Quang, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410647 · Cited by 150
Structure of Telomerase with Telomeric DNA
Jiang, J., Wang, Y., Sušac, L., Chan, H., Basu, R., Zhou, Z. H., & Feigon, J. (2018) · Cell · doi:10.1016/j.cell.2018.04.038 · Cited by 150
DNA nanotechnology approaches for microRNA detection and diagnosis
Chandrasekaran, A. R., Punnoose, J. A., Zhou, L., Dey, P., Dey, B. K., & Halvorsen, K. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz580 · Cited by 154
“Nucleic acid analogs such as peptide nucleic acid (PNA) and locked nucleic acid (LNA) with different base pairing affinities can also be added to tune or improve specificity (162,163).”
BackgroundPolitz, J. C. R., Zhang, F., & Pederson, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609466103 · Cited by 150
Aigner, A. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0716-0 · Cited by 152
“that locked nucleic acid (LNA)-modified anti-miRNA oligonucleotides [77] were able to inhibit miR-21 in”
Structure of Tetrahymena telomerase reveals previously unknown subunits, functions, and interactions
Jiang, J., Chan, H., Cash, D. D., Miracco, E. J., Ogorzalek Loo, R. R., Upton, H. E., Cascio, D., O’Brien Johnson, R., Collins, K., Loo, J. A., et al. (2015) · Science · doi:10.1126/science.aab4070 · Cited by 146
de Planell-Saguer, M., Rodicio, M., & Mourelatos, Z. (2010) · Nature Protocols · doi:10.1038/nprot.2010.62 · Cited by 141
“Another major improvement in standard FISH and CISH protocols was the substitution of traditional DNA or RNA probes with LNA-modified oligonucleotide probes, which display markedly increased hybridization affinities toward complementary RNAs, compared with traditional RNA- or DNA-based probe”
BackgroundLangkjær, N., Pasternak, A., & Wengel, J. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.06.045 · Cited by 150
Self-citationmicroRNAs: a new emerging class of players for disease diagnostics and gene therapy
Zhang, B., & Farwell, M. A. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00196.x · Cited by 157
Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer
Diamantopoulos, M. A., Tsiakanikas, P., & Scorilas, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.10 · Cited by 148
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma
Arcila, M. E., Lau, C., Nafa, K., & Ladanyi, M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.005 · Cited by 148
Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide
Kawakami, S., Higuchi, Y., & Hashida, M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21024 · Cited by 140
Micrornas in prostate cancer: an overview
Vanacore, D., Boccellino, M., Rossetti, S., Cavaliere, C., D’Aniello, C., Franco, R. D., Romano, F. J., Montanari, M., Mantia, E. L., Piscitelli, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16933 · Cited by 152
“LNA oligonucleotides have a big ability to hybridize complementary single- or double-stranded DNA and complementary single-stranded RNA [59].”
BackgroundIn vitro quantification of specific microRNA using molecular beacons
Baker, M. B., Bao, G., & Searles, C. D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1016 · Cited by 140
“In addition, there have been reports illustrating enhanced affinity of LNA bases for oligonucleotides in cells (35).”
BackgroundCastoldi, M., Schmidt, S., Beneš, V., Hentze, M. W., & Muckenthaler, M. U. (2008) · Nature Protocols · doi:10.1038/nprot.2008.4 · Cited by 141
INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes
Sherman, E. A., Nobles, C. L., Berry, C. C., Six, E. M., Wu, Y., Dryga, A., Malani, N., Male, F., Reddy, S. G., Bailey, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.002 · Cited by 134
Briones, C., & Moreno, M. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-5742-z · Cited by 138
“(reviewed elsewhere [23, 108, 109]).”
Locked nucleic acid as a novel class of therapeutic agents
Veedu, R. N., & Wengel, J. (2009) · RNA Biology · doi:10.4161/rna.6.3.8807 · Cited by 124
Self-citationRecent advances in DNAzyme-based gene silencing
Fan, H., Zhang, X., & Lu, Y. (2017) · Science China Chemistry · doi:10.1007/s11426-016-0472-1 · Cited by 122
Fattal, E., & Bochot, A. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.06.011 · Cited by 131
Dalmay, T. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01926.x · Cited by 121
microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases
Basak, I., Patil, K. S., Alves, G., Larsen, J. P., & Møller, S. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2093-x · Cited by 107
A review of reaction enhancement strategies for isothermal nucleic acid amplification reactions
Özay, B., & McCalla, S. E. (2021) · Sensors and Actuators Reports · doi:10.1016/j.snr.2021.100033 · Cited by 136
Kierzek, E. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki789 · Cited by 117
“A modification that is particularly stabilizing in DNA and RNA duplexes (44–51) is a methyl bridge between the 2 0 oxygen and 4 0 carbon of ribose to form a ‘locked nucleic acid’ or LNA as shown in Figure 1.”
miRNAS in normal and diseased skeletal muscle
Eisenberg, I., Alexander, M. S., & Kunkel, L. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00524.x · Cited by 133
“Locked nucleic acids are more stable than single-stranded RNA molecules due to a modification of the ribose moiety of the oligonucleotide that results in enhanced stability and greater resistance to increases in temperature (reviewed in [57]).”
BackgroundCerqueira, L., Azevedo, N. F., Almeida, C., Jardim, T., Keevil, C. W., & Vieira, M. J. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9101944 · Cited by 138
“formed with 2’-O, 4’-C-methylene-ß-Dribofuranosyl nucleotides (Figure 1) [32, 52].”
MicroRNA-182 plays an onco-miRNA role in cervical cancer
Tang, T., Wong, H. K., Gu, W., Yu, M., To, K., Wang, C. C., Wong, Y. F., Cheung, T. H., Chung, T. K. H., & Choy, K. W. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.043 · Cited by 114
“We further used the LNA modified oligonucleotide probes for in situ hybridization (ISH) to identify its cellular and subcellular distribution of miRNAs in cervical carcinoma [17].”
MethodKnockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe
Lamers, F., van der Ploeg, I., Schild, L. G., Ebus, M. E., Köster, J., Hansen, B. R., Koch, T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0207 · Cited by 113
“RNA interference functions via the RISC, which can bind and cleave the target mRNA (Rubinson et al. 2003) while LNA-ASO such as EZN-3042 bind mRNA, and activates RNAse H-dependent mRNA cleavage (Petersen & Wengel 2003, Vester & Wengel 2004, Hansen et al. 2008).”
BackgroundNoninvasive imaging of Staphylococcus aureus infections with a nuclease-activated probe
Hernández, F. J., Huang, L., Olson, M. E., Powers, K. M., Hernandez, L. I., Meyerholz, D. K., Thedens, D. R., Behlke, M. A., Horswill, A. R., & McNamara, J. O. (2014) · Nature Medicine · doi:10.1038/nm.3460 · Cited by 111
Liu, X.-Q., Song, W.-J., Sun, T.-M., Zhang, P.-Z., & Wang, J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100315q · Cited by 108
Chakraborty, C., Sharma, A. R., Sharma, G., Sarkar, B. K., & Lee, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24309 · Cited by 112
“Some are locked nucleic acid or LNA [36], antisense antimiR oligonucleotides [37], small molecule inhibitors of miRNAs [38] and miRNA sponges [39, 40].”
BackgroundPourshahian, S. (2019) · Mass Spectrometry Reviews · doi:10.1002/mas.21615 · Cited by 119
MicroRNAs as therapeutic targets in human cancers
Shah, M., & Călin, G. A. (2014) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1229 · Cited by 122
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing
Rigo, F., Hua, Y., Chun, S. J., Prakash, T. P., Krainer, A. R., & Bennett, C. F. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.939 · Cited by 102
MicroRNAs as biomarkers and therapeutic drugs in human cancer
Osaki, M., Takeshita, F., & Ochiya, T. (2008) · Biomarkers · doi:10.1080/13547500802646572 · Cited by 108
Improved In Situ Hybridization Efficiency with Locked-Nucleic-Acid-Incorporated DNA Probes
Kubota, K., Ohashi, A., Imachi, H., & Harada, H. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03039-05 · Cited by 108
Fattal, E., & BARRATT, G. M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00148.x · Cited by 114
“This was accompanied by an increased inhibition of NF-kB activation (80-fold higher than with naked decoy ODN), as suggested by decreased NO production, inducible nitric oxide synthase and TNF, tumour necrosis factor-a (TNF-a) expression as well as reduced NF-kB/DNA binding (De Rosa et al., 2005).”
BackgroundInfluential
Metadata
- Authors
- Vester, B., & Wengel, J.
- Affiliations
- University of Southern Denmark (DK)
- Corresponding author
- Vester, Birte
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-10-01
- Volume
- 43
- Issue
- 42
- Pages
- 13233-13241
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2139273728
- Cited by
- 727
- References
- 57
- Citations by year
- 2026: 19 · 2025: 34 · 2024: 23 · 2023: 28 · 2022: 38 · 2021: 32 · 2020: 26 · 2019: 27 · 2018: 32 · 2017: 24 · 2016: 40 · 2015: 34 · 2014: 45 · 2013: 35 · 2012: 54
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Keywords
- locked nucleic acid, LNA oligonucleotides, nucleic acid analogs, hybridization affinity, gene silencing, nucleic acid diagnostics, RNA mimics
- MeSH terms
- Endoribonucleases, Hydrolysis, Nucleic Acid Conformation, Nucleotides, Oligonucleotides, Ribose, Oligonucleotides, Antisense, RNA, Complementary, DNA, Complementary, Molecular Mimicry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.